e-learning
resources
Munich 2014
Sunday, 07.09.2014
Asthma and COPD devices and treatments
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Mometasone furoate delivered via the Breezhaler
®
and Twisthaler
®
devices in asthma
F. Kanniess, G. Hanf, M. Hosoe, A. M. Tanase, S. Vaidya, R. Banerjee, B. Hederer (Reinfeld, Berlin, Germany; Basel, Switzerland; Cambridge, United States Of America; Hyderabad, India)
Source:
International Congress 2014 – Asthma and COPD devices and treatments
Session:
Asthma and COPD devices and treatments
Session type:
Thematic Poster Session
Number:
915
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Kanniess, G. Hanf, M. Hosoe, A. M. Tanase, S. Vaidya, R. Banerjee, B. Hederer (Reinfeld, Berlin, Germany; Basel, Switzerland; Cambridge, United States Of America; Hyderabad, India). Mometasone furoate delivered via the Breezhaler
®
and Twisthaler
®
devices in asthma. Eur Respir J 2014; 44: Suppl. 58, 915
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Plume temperature and force of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014
Lung deposition analysis of two formulations of fluticasone/salmeterol HFA pMDI in stable asthma patients
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Mixed treatment analysis comparing tiotropium HandiHaler
®
and Respimat
®
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium-high dose of inhaled corticosteroids
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Mometasone furoate delivered via Breezhaler and Twisthaler in patients with asthma
Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts
Year: 2019
Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Pharmacokinetics (PK) of indacaterol acetate and mometasone furoate delivered alone or in combination following once daily inhalation in healthy subjects
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Pharmacokinetics (PK), safety and tolerability of abediterol and mometasone furoate fixed- and free-dose combinations in healthy subjects
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Dose-proportional lung bioavailability of beclometasone dipropionate and formoterol fumarate across three different dose strenghts of CHF1535 pMDI
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
Efficacy and safety of indacaterol acetate on ICS background therapy in asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
In vitro lung deposition of fluticasone propionate/formoterol (FP/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Plume characteristics of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013
Interaction between aclidinium bromide and formoterol fumarate in small human airways
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Evaluation of systemic exposure between two nasal spray formulations of mometasone furoate in healthy subjects
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Effect of inhaled vilanterol trifenatate/fluticasone furoate on breathing pattern, dyspnea and respiratory muscle function in severe COPD
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014
24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma
Source: International Congress 2015 – Immune mechanisms in the human lung
Year: 2015
Formoterol Aerolizer inhaler technique in patients with Asthma and COPD
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017
Interaction between RPL554 and glycopyrronium bromide in small human airways
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept